Free Trial

Codexis (CDXS) Stock Price, News & Analysis

Codexis logo
$2.42 0.00 (0.00%)
Closing price 09/5/2025 04:00 PM Eastern
Extended Trading
$2.49 +0.07 (+2.89%)
As of 09/5/2025 07:49 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Codexis Stock (NASDAQ:CDXS)

Key Stats

Today's Range
$2.40
$2.50
50-Day Range
$2.40
$3.33
52-Week Range
$1.90
$6.08
Volume
722,273 shs
Average Volume
1.40 million shs
Market Capitalization
$218.45 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$11.00
Consensus Rating
Moderate Buy

Company Overview

Codexis Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
75th Percentile Overall Score

CDXS MarketRank™: 

Codexis scored higher than 75% of companies evaluated by MarketBeat, and ranked 256th out of 932 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Codexis has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 1 buy rating, 1 hold rating, and no sell ratings.

  • Upside Potential

    Codexis has a consensus price target of $11.00, representing about 354.5% upside from its current price of $2.42.

  • Amount of Analyst Coverage

    Codexis has received no research coverage in the past 90 days.

  • Read more about Codexis' stock forecast and price target.
  • Earnings Growth

    Earnings for Codexis are expected to grow in the coming year, from ($0.77) to ($0.66) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Codexis is -2.92, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Codexis is -2.92, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Codexis has a P/B Ratio of 2.95. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about Codexis' valuation and earnings.
  • Percentage of Shares Shorted

    5.75% of the outstanding shares of Codexis have been sold short.
  • Short Interest Ratio / Days to Cover

    Codexis has a short interest ratio ("days to cover") of 4.9.
  • Change versus previous month

    Short interest in Codexis has recently decreased by 6.82%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Codexis does not currently pay a dividend.

  • Dividend Growth

    Codexis does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    5.75% of the outstanding shares of Codexis have been sold short.
  • Short Interest Ratio / Days to Cover

    Codexis has a short interest ratio ("days to cover") of 4.9.
  • Change versus previous month

    Short interest in Codexis has recently decreased by 6.82%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    Codexis has a news sentiment score of 1.67. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.72 average news sentiment score of Medical companies.
  • Search Interest

    3 people have searched for CDXS on MarketBeat in the last 30 days. This is an increase of 50% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Codexis insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 1.90% of the stock of Codexis is held by insiders.

  • Percentage Held by Institutions

    78.54% of the stock of Codexis is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Codexis' insider trading history.
Receive CDXS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Codexis and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

CDXS Stock News Headlines

Codexis Inc. (CDXS) Stock Price Today - WSJ
Odd trade could help investors secure their wealth in 2025
The most profitable phrase you’ve never heard of... Have you heard of 310F? This simple string of code could hand investors 100% gains in just 72 hours. Really. This code has spit out 904 winning trades out of 926 closed positions since 2015. That’s a 97.6% success rate. It’s designed to pay out a 100% gain (or more). And always on Friday.tc pixel
Codexis: Q2 Earnings Snapshot
Q2 2025 Codexis Inc Earnings Call Transcript
See More Headlines

CDXS Stock Analysis - Frequently Asked Questions

Codexis' stock was trading at $4.77 at the beginning of the year. Since then, CDXS stock has decreased by 49.3% and is now trading at $2.42.

Codexis, Inc. (NASDAQ:CDXS) released its quarterly earnings results on Wednesday, August, 13th. The biotechnology company reported ($0.16) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.17) by $0.01. The biotechnology company earned $15.33 million during the quarter, compared to analysts' expectations of $14.18 million. Codexis had a negative net margin of 113.67% and a negative trailing twelve-month return on equity of 105.83%.
Read the conference call transcript
.

Codexis' top institutional shareholders include Opaleye Management Inc. (15.21%), Aberdeen Group plc (5.07%), Nantahala Capital Management LLC (4.87%) and Telemark Asset Management LLC (4.83%). Insiders that own company stock include Opaleye Management Inc, John J Nicols, Byron L Dorgan, Sriram Ryali, Kevin Norrett and Margaret Nell Fitzgerald.
View institutional ownership trends
.

Shares of CDXS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Codexis investors own include Tesla (TSLA), NVIDIA (NVDA), Advanced Micro Devices (AMD), Meta Platforms (META), Netflix (NFLX), Walt Disney (DIS) and JPMorgan Chase & Co. (JPM).

Company Calendar

Last Earnings
8/13/2025
Today
9/06/2025
Next Earnings (Estimated)
10/30/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:CDXS
CIK
1200375
Employees
250
Year Founded
N/A

Price Target and Rating

High Price Target
$11.00
Low Price Target
$11.00
Potential Upside/Downside
+354.5%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
2 Analysts

Profitability

EPS (Trailing Twelve Months)
($0.83)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$65.28 million
Net Margins
-113.67%
Pretax Margin
-113.61%
Return on Equity
-105.83%
Return on Assets
-46.06%

Debt

Debt-to-Equity Ratio
0.71
Current Ratio
5.82
Quick Ratio
5.70

Sales & Book Value

Annual Sales
$59.35 million
Price / Sales
3.68
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.82 per share
Price / Book
2.95

Miscellaneous

Outstanding Shares
90,270,000
Free Float
88,552,000
Market Cap
$218.45 million
Optionable
Optionable
Beta
2.54
7 Stocks to Buy And Hold Forever Cover

Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

This page (NASDAQ:CDXS) was last updated on 9/6/2025 by MarketBeat.com Staff
From Our Partners